美股新聞 標題聯播 · 近 24 小時 284 則 · 25 個來源 · 最新 9/20 06:32
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · CYTK近 30 天 11 則 · 第 1 / 1 頁
- Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
- Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says
- Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?
- Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
- Cytokinetics (CYTK) Reaches A Phase 3 First In Non Obstructive HCM
- Jefferies starts biopharma firm Braveheart at Buy after IPO
- ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
- Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
- Cytokinetics Boasts A First-Ever In Heart Disease — And Shares Drop
- Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine
- Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?
- Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
- Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
- Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
- Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。